IDT Biologika To Expand Viral Vaccine Capacity

IDT Biologika has announced plans to expand its viral vaccine production capacity with the addition of a new high-speed filling line and additional lyophilization capacity. The company also announced the addition of 80 employees to its workforce — a boost of 11 % — to meet growth in demand for biologics production.

The company plans to expand its flexible, multipurpose vaccine manufacturing facilities via the completion of its new high-speed viral vaccine line by mid-2013. This line will substantially expand fill-finish capacity and well position the company for anticipated growth in demand. The company’s existing vaccine facility features two contained manufacturing lines with segregated operations for preparation of cells, virus propagation and virus purification. All IDT Biologika facilities have been inspected by international regulatory agencies such as the FDA and EMA.

Dr. Ralf Pfirmann, chief executive officer of IDT Biologika, said, “We are proud to be one of the few industrial service manufacturers in the world with the capacity and expertise to handle large-scale campaign manufacture of various vaccines and biopharmaceuticals. In light of the resurgence of interest by large pharma in developing new vaccines and the planned expansion of our filling capacity, IDT remains well positioned to provide ongoing best-in-class service to these innovative companies, from the bench through clinical development and commercial production.”